Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sector

Biotech

Everything our editor has picked under this sector, best first.

167 stories

@KEDM_COM 4 clicks

KEDM.com on X

ProQR Therapeutics $PRQR CEO Daniel de Boer bought $513K across two separate purchases on July 7 and July 9, and a company director bought another $229.5K in late June (real money for a Dutch CEO). PRQR is a small-cap RNA-editing biotech backed by a major pharma partner: Eli Lilly. Their collaboration, running since 2021 and expanded in 2022, could pay ProQR up to $3.75 billion in milestones plus royalties, real validation for a company this size. The balance sheet just got stronger too: ProQR raised roughly $59 million in late June 2026, with Lilly buying in alongside the public offering to keep its stake intact, a vote of confidence from the partner who knows their science best.
@BrokenMoats 3 clicks

Broken Moats on X

$DNA another perfectly rational move, happens daily across this low quality business, low quality balance sheet biotech tangential name space (ironically while actual biotech names sell off due to rates). My biggest question is why are these co. not raising $$$, all of them need money in this basket and their stock prices are up 100's% points in a very short period of time (few months). Wh not stretch the life of the company and fix the balance sheets?
@SowingAlphaSeed 2 clicks

Farmer on X

You look at $LQDA? Just received this letter. "Liquidia was on track to generate $1.4 billion in revenue in 2027. Half of the revenue so far has been from PAH and half from PH-ILD. Net margins are likely to be in the 50% range. If PH-ILD is removed, we assume $700 million in revenue and $350 million in cash flow. At a reasonable multiple, we would be looking at a stock value from that sales market between $44 and $55. If there is a 30% royalty on PH-ILD sales, we would have $350 million in cash flow from PAH and $245 million in cash flow from PH-ILD sales. At a reasonable multiple, we would be looking at a stock value from that sales market between $75 and $94." https://t.co/CatQzuyQ1C
@KEDM_COM 2 clicks

KEDM.com on X

Qiagen $QGEN has a new CEO (Jonathan Pratt) per Sept. 1. Let's see if he can bring some action. The company also recently confirmed it continues to evaluate strategic alternatives, with Goldman Sachs involved. There have been reports of takeover interest for a long time, with past reports linking Qiagen to Thermo Fisher, bioMérieux, and Bio-Rad. Qiagen is an interesting target given its leadership in nucleic acid prep, strong consumables-driven revenue, and growth areas like TB testing and digital PCR. The portfolio would fit well with major industry consolidators.
@BrokenMoats

Broken Moats on X

Someone really should investigate the price action into some of these ancillary biotech stocks.....very reminiscent of a certain Situational Awareness with chip stocks earlier in the year. No one is filing ownership and yet these stocks push higher regardless of macro, or geopolitical news or the overall index moves. Someone with swaps? or options likely at play then using the momentum pf retail and algos to add to the bid. The trade is melting up perfectly to the end of the quarter (not surprised to see them even more aggressively up today than usual to mark performance). We saw this with the chips trade after an unprecedented April-June. But some of the moves with this trade exceed that euphoria (Look at $TXG, $TWST, $SDGR, $RGEN, $GRAL, and a host of other companies)........DO we see the similar move after a giant quarter with a reversal to kick of the next quarter, that was the fate with chips and caused the fund to blow up. Be interesting to see if they learned any lessons, Im guessing not based on recent performance, and if it is a different player the strategy looks the same. These companies need financing and should hit the market bid which is what set off Viacom and was the undoing of Bill Huang in 2021. Lets see, but a basket of these stocks looks interesting at current levels sometime today for gravity/secondaries to come early in Q4
SEER · long

Seer INC

SEER Inc became a founder-offer special situation just before publication.

SEER $124M
Value Investors Club 2 clicks